Gliknik Inc.
Gliknik Inc. is a privately owned corporation committed to the discovery and development of novel biomolecules for autoimmune diseases and cancer. The company capitalizes on its expertise in immunology and tumor immunology. Gliknik’s lead compounds are novel T cell vaccines in clinical safety studies. Gliknik also has created recombinant mimetics of intravenous immune globulin and recombinant mimetics of monoclonal antibodies.
Contact Name:
David Block
President & CEO
Address:
801 W. Baltimore Street
Suite 501A
Baltimore Maryland 21201
United StatesEmail:
Website:
News
America's Most Promising Start-ups
Posted July 7, 2010
Maryland Health Care Product Development Corporation Invests in Gliknik Inc.
Posted June 8, 2010
Multiplatform Gliknik Tackling Cancer, Immune Disease Markets
Posted January 21, 2010
Gliknik Inc. closes in on $3M funding round
Posted September 2, 2009
Pages
- ‹ previous
- …
- 2
- 3
- 4
- next ›